Table 3 Response rate

From: A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

 

Cis/Doc ( n =43)

Ox/Doc ( n =43)

 

No.

%

No.

%

RR*

20

47a

12

28

CR

1

2

1

2

PR

19

44

11

26

SD

12

30

15

35

PD

3

7

11

26

NE

8

19

5

12

  1. Abbreviations: Cis/Doc=cisplatin/docetaxel; Ox/Doc=oxaliplatin/docetaxel; CR=complete response; PR=partial response; RR=response rate; SD=stable disease; PD=progressive disease; NE=not evaluable.
  2. aCis/Doc: 95% CI (confidence interval): 0.3251–0.6109; Ox/Doc: 95% CI: 0.1663–0.4281.*P-value=0.1178.
Back to article page